An 8-21 fold multiplication of myeloid cells and macrophages was observed in tissue culture from human fetal bone marrow. Proliferation of the cells was triggered by medium conditioned by acute myelocytic leukemic cells exposed to 12-O-tetradecanoyl phorbol 13-acetate (TPA). The medium was designated as TPA-treated cell conditioned medium (TPACCM). The cycle of events in fetal bone marrow cell culture began with a sharp decrease in the total number of cells. At this juncture a predominance of primitive macrophage-like cells positive for macrophage markers was present in the culture. The process of multiplication began with rapid proliferation of promyelocytes. Simultaneous proliferation of granulocyte-macrophage (GM) colony forming cells (CFC) indicated that at least some of the promyelocytes might act like CFC. The absolute number of committed CFC then increased 5-11 fold, the number that approximated a total multiplication of FBM cells. The proliferation continued with the culture containing some blast cells and showing simultaneous differentiation of the cells into mature granulocytes and macrophages. The cells with macrophage markers persisted throughout the culture period. To determine more precise definition of the role of primitive macrophages and promyelocytes in FBM cell multiplication, experiments with purified fractions of these cells have to be done. TPACCM purification and isolation of active substances is also suggested. These investigations might result in obtaining a pool of BM cells in vitro suitable for BM transplantation.

Download full-text PDF

Source

Publication Analysis

Top Keywords

cells
13
human fetal
8
medium conditioned
8
conditioned acute
8
acute myelocytic
8
12-o-tetradecanoyl phorbol
8
phorbol 13-acetate
8
13-acetate tpa
8
fetal bone
8
bone marrow
8

Similar Publications

Drug Development.

Alzheimers Dement

December 2024

ECU, Perth, Western Australia, Australia.

Background: The autophagy lysosomal pathway (ALP) and the ubiquitin-proteasome system (UPS) are key proteostasis mechanisms in cells, which are dysfunctional in AD and linked to protein aggregation and neuronal death. Autophagy is over activated in Alzheimer's disease brain whereas UPS is severely impaired. Activating autophagy has received most attention, however recent evidence suggests that UPS can clear aggregate proteins and a potential therapeutic target for AD and protein misfolding diseases.

View Article and Find Full Text PDF

Drug Development.

Alzheimers Dement

December 2024

Aptah Bio Inc., San Carlos, CA, USA.

Background: Alzheimer's disease (AD) is the most common cause of dementia worldwide. It is characterized by dysfunction in the U1 small nuclear ribonucleoproteins (snRNPs) complex, which may precede TAU aggregation, enhancing premature polyadenylation, spliceosome dysfunction, and causing cell cycle reentry and death. Thus, we evaluated the effects of a synthetic single-stranded cDNA, called APT20TTMG, in induced pluripotent stem cells (iPSC) derived neurons from healthy and AD donors and in the Senescence Accelerated Mouse-Prone 8 (SAMP8) model.

View Article and Find Full Text PDF

Background: Immunotherapy of Alzheimer's disease (AD) is a promising approach to reducing the accumulation of beta-amyloid, a critical event in the onset of the disease. Targeting the group II metabotropic glutamate receptors, mGluR2 and mGluR3, could be important in controlling Aβ production, although their respective contribution remains unclear due to the lack of selective tools.

Method: 5xFAD mice were chronically treated by a brain penetrant camelid single domain antibody (VHH or nanobody) that is an activator of mGluR2.

View Article and Find Full Text PDF

Background: Genetic studies indicate a causal role for microglia, the innate immune cells of the central nervous system (CNS), in Alzheimer's disease (AD). Despite the progress made in identifying genetic risk factors, such as CD33, and underlying molecular changes, there are currently limited treatment options for AD. Based on the immune-inhibitory function of CD33, we hypothesize that inhibition of CD33 activation may reverse microglial suppression and restore their ability to resolve inflammatory processes and mitigate pathogenic amyloid plaques, which may be neuroprotective.

View Article and Find Full Text PDF

Background: Our previous study identified that Sildenafil (a phosphodiesterase type 5 [PDE5] inhibitor) is a candidate repurposable drug for Alzheimer's Disease (AD) using in silico network medicine approach. However, the clinically meaningful size and mechanism-of-actions of sildenafil in potential prevention and treatment of AD remind unknown.

Method: We conducted new patient data analyses using both the MarketScan® Medicare with Supplemental database (n = 7.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!